BAYER AKTIENGESELLSCHAFT - 22 Jun 2021 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Reporting relationship: 10%+ Owner
Issuer ticker: IPSC
Reported as of: 22 Jun 2021
Net transaction value: +$15,000,000
SEC form: 4
Accepted by SEC: 23 Jun 2021, 16:41:21 UTC
Prior SEC filing: 17 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Christian Bank, on behalf of Bayer Aktiengesellschaft

Key filing fact

BAYER AKTIENGESELLSCHAFT filed Form 4 for Century Therapeutics, Inc. (IPSC) on 23 Jun 2021.

Key facts

This page summarizes BAYER AKTIENGESELLSCHAFT's Form 4 filing for Century Therapeutics, Inc. (IPSC).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jun 2021, 16:41.

Change

Previous filing in this sequence was filed on 17 Jun 2021.
Current net transaction value: +$15,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IPSC transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +10,390,600
Change %
Price
Shares after: 10,390,600
Date: 22 Jun 2021
Ownership: Direct
Footnotes: F1, F2

IPSC transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +1,535,238
Change %: +15%
Price
Shares after: 11,925,838
Date: 22 Jun 2021
Ownership: Direct
Footnotes: F2, F3

IPSC transaction

Common Stock

Purchase

Transaction value: $15,000,000
Shares: +750,000
Change %: +6.3%
Price: $20.00^*
Shares after: 12,675,838
Date: 22 Jun 2021
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IPSC transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -26,143,790
Change %: -100%
Price
Shares after: 0
Date: 22 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,390,600
Exercise price
Footnotes: F1, F2

IPSC transaction Derivative

Series C Preferred Stock

Conversion of derivative security

Transaction value
Shares: -3,862,813
Change %: -100%
Price
Shares after: 0
Date: 22 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,535,238
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date.

Footnote F2

The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.

Footnote F3

Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date.